<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168009">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01690299</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-010</org_study_id>
    <secondary_id>2012-000859-14</secondary_id>
    <nct_id>NCT01690299</nct_id>
  </id_info>
  <brief_title>Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis</brief_title>
  <official_title>A Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the clinical effectiveness and safety of apremilast, etanercept
      compared with placebo in the same group of patients with moderate to severe plaque
      psoriasis.

      Apremilast (CC-10004) is a new oral agent that is under clinical development for the
      treatment of inflammatory autoimmune disorders, such as psoriatic arthritis, psoriasis,
      rheumatoid arthritis, and Beh√ßet disease.

      Etanercept is approved for the treatment of psoriasis; it is the most widely prescribed
      anti-tumor  necrosis factor (TNF) for psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3b, multicenter, randomized, placebo-controlled, double-blind, double-dummy,
      study of the efficacy and safety of apremilast, etanercept, and placebo, in subjects with
      moderate to severe plaque psoriasis.

      Approximately 240 subjects will be randomized 1:1:1 to the three treatment groups.  All
      subjects will receive both tablets and injections through Week 16.

      The study will consist of four phases:

        -  Screening Phase - up to 35 days

        -  Double-blind Placebo-controlled Phase - Weeks 0-16

        -  Apremilast Extension Phase - Weeks 16-104

        -  Post-treatment Observational Follow-up Phase

      During the double-blind, placebo-controlled phase, subjects will receive treatment with one
      of the following:

        -  apremilast (APR) 30 mg tablets orally twice a day (BID) plus once weekly (QW)
           evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections (1 mL x 2
           injections SC), or

        -  etanercept (ETN) 50 mg evaluator/subject-blinded subcutaneous (SC) once weekly (QW)
           injections (2 x 25 mg) plus placebo tablets orally twice a day (BID),  or

        -  placebo tablets and evaluator/subject-blinded subcutaneous (SC) saline (placebo)
           injections.

      All subjects will be asked to participate in a 4-week Post-treatment Observational Follow-up
      Phase either upon completion of the study or upon discontinuation of investigational product
      for those subjects who terminate the study early.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Apremilast Psoriasis Area and Severity Index-75 (PASI)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects with either apremilast 30 mg twice a day (BID) or placebo who achieve at least a 75% reduction in PASI (PASI-75) at Week 16 from baseline in subjects with plaque type psoriasis or plaque psoriasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Etanercept Psoriasis Area and Severity Index-75 (PASI)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects treated with either etanercept 50mg once weekly (QW) or placebo who achieve PASI-75 (at least a 75% reduction in PASI from baseline in subjects with plaque type psoriasis or plaque psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Severity Score</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects with a Static Physician's Global Assessment (sPGA) of overall disease severity score of clear (0) or almost clear (1) with at least 2 points reduction from baseline in subjects with plaque type psoriasis or plaque psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in the body surface area (BSA) affected by psoriasis</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline in the body surface area (BSA) affected by psoriasis in subjects with plaque type psoriasis or plaque psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index-50 (PASI)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects who achieve PASI-50 (at least a 50% reduction in PASI from baseline) in subjects with plaque type psoriasis or plaque psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in the Dermatology Life Quality Index (DLQI) total score in subjects with plaque type psoriasis or plaque psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental Component Summary (MCS)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in the Mental Component Summary (MCS) score of the Medical Outcome Study Short Form 36 - item Health Survey (SF-36) in subjects with plaque type psoriasis or plaque psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lattice System Physician's Global Assessment (LS-PGA)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects with a Lattice System Physician's Global Assessment (LS-PGA) of psoriasis severity score of clear (0) or almost clear (1) in subjects with plaque type psoriasis or plaque psoriasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>Week 16 and week 104</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adverse events in subjects with plaque type psoriasis or plaque psoriasis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Apremilast 30 mg plus placebo injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept 50 mg plus placebo tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast tablet/pill 30 mg</intervention_name>
    <description>Apremilast tablet/pill 30 mg tablet orally twice a day</description>
    <arm_group_label>Apremilast 30 mg plus placebo injection</arm_group_label>
    <other_name>CC-10004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept 50 mg</intervention_name>
    <description>Etanercept 50 mg evaluator/subject-blinded subcutaneous once weekly injection</description>
    <arm_group_label>Etanercept 50 mg plus placebo tablet</arm_group_label>
    <other_name>ETN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablets twice a day</description>
    <arm_group_label>Etanercept 50 mg plus placebo tablet</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection (saline)</intervention_name>
    <description>once weekly evaluator/subject-blinded subcutaneous saline (placebo) injections (1 mL x 2 injections SC)</description>
    <arm_group_label>Apremilast 30 mg plus placebo injection</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, ‚â• 18 years of age

          -  Diagnosis of chronic, moderate to severe plaque psoriasis for at least 12 months
             prior to Screening, and a candidate for phototherapy and/or systemic (including
             etanercept) therapy

          -  Had an inadequate response, intolerance, or contraindication to at least 1
             conventional systemic agent for the treatment of psoriasis.

          -  No prior exposure to biologics for treatment of psoriatic arthritis or psoriasis

        Exclusion Criteria:

          -  Other than psoriasis, history of any clinically significant and uncontrolled systemic
             diseases; any condition, including the presence of laboratory abnormalities, which
             would place the subject at unacceptable risk if he/she were to participate in the
             study.

          -  Pregnant or breast feeding.

          -  Have failed more than 3 systemic agents for treatment of psoriasis.

          -  History of allergy to any component of the investigational product (IP), including
             human immunoglobulin (Ig) proteins or allergy to etanercept.

          -  Hepatitis B surface antigen or anti-hepatitis C antibody positive at Screening.

          -  Latent, active tuberculosis (TB) or inadequately treated TB; nontuberculous
             mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis
             carinii, aspergillosis, Clostridium difficile).

          -  Have a history of, or ongoing, chronic or recurrent infectious disease

          -  Have received, or are expected to receive, any live virus or bacterial vaccination
             within  3 months before first administration of IP, or through Week 20 during the
             study.

          -  Had a Bacillus Calmette-Gu√©rin (BCG) vaccination within 1 year prior to screening.

          -  History of positive human immunodeficiency virus (HIV), or have congenital or
             acquired immunodeficiency (eg, common variable immunodeficiency disease).

          -  Active substance abuse or a history of substance abuse within 6 months prior to
             Screening.

          -  Malignancy or history of malignancy, except for treated [ie, cured] basal cell or
             squamous cell in situ skin carcinomas and cervical intraepithelial neoplasia [CIN] or
             carcinoma in situ of the cervix with no evidence of recurrence within the previous 5
             years.

          -  Psoriasis flare or rebound within 4 weeks prior to Screening.

          -  Topical therapy within 2 weeks of randomization or  systemic therapy for psoriasis
             within 4 weeks prior to randomization

          -  Use of phototherapy within 4 weeks prior to randomization or prolonged sun exposure
             or use of tanning booths or other ultraviolet (UV) light sources.

          -  Any investigational drug within 4 weeks prior to randomization, or 5
             pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).

          -  Prior treatment with apremilast or etanercept.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilia Pineda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakersfield Dermatology and Skin Cancer Medical Group</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>99309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizons Clinical Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates Clinical Trials Unit</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Academic Dermatology Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Center for Dermatology, PA</name>
      <address>
        <city>St. Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology, Vein &amp; Research Center</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Health System</name>
      <address>
        <city>Shokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine Dermatology/Internal Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Advanced Aesthetics</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence Green, MD, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School/UMDNJ Department of Dermatology</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forest Hills Dermatology Group</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Department of Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100616-6402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University, Division of Dermatology</name>
      <address>
        <city>Gahanna</city>
        <state>Ohio</state>
        <zip>43230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teckton Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education and Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialist Connect</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4201</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fremantle Dermatology</name>
      <address>
        <city>Freemantle</city>
        <state>Western Australia</state>
        <zip>6160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burswood Dermatology</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc, Dermatology</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent, Dermatology</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liege, Dermatology Department</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Canada Cutaneous Research Associates Ltd</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Q&amp;T Research</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermamedica</name>
      <address>
        <city>Nachod</city>
        <zip>54701</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajsk√° nemocnice Pardubice, Ko≈æn√≠ oddelen√≠</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ko≈æn√≠ ordinace</name>
      <address>
        <city>Svitavy-Predmest√≠</city>
        <zip>568 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ko≈æn√≠ a ≈æiln√≠ ambulance</name>
      <address>
        <city>√öst√≠ nad Labem</city>
        <zip>400 10</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Estonian Hospital Ltd</name>
      <address>
        <city>Meegomae Village, Voru County</city>
        <zip>65526</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinic of Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>50417</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Mahlow</name>
      <address>
        <city>Mahlow</city>
        <state>BB</state>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Study Centre (Clinic of Dermatology, Venerology and Allergology)</name>
      <address>
        <city>Berlin</city>
        <state>BE</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautklinik Universit√§tsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>BY</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt (Department of Dermatology, Venerology and Allergology)</name>
      <address>
        <city>Frankfurt / Main</city>
        <state>HE</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Health Services, Research in Dermatology and Nursing - IVDP, University Medical Center of Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <state>HH</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCIderm GmbH</name>
      <address>
        <city>Hamburg</city>
        <state>HH</state>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital M√ºnster (Dermatology)</name>
      <address>
        <city>M√ºnster</city>
        <state>NW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus, Department of Dermatology</name>
      <address>
        <city>Dresden</city>
        <state>SN</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§tsKlinikum Leipzig A.√∂.R., Department f. Innere Medizin, Neurologie II, Dermatologie Klinik und Poliklinik f√ºr Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Leipzig</city>
        <state>SN</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologische Praxis</name>
      <address>
        <city>Berlin</city>
        <zip>10827</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin - Buch GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Center of Inflammatory Medicine (CCIM) University Medical Center Schleswig-Holstein</name>
      <address>
        <city>L√ºbeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fr Dermatologie und Venerologie</name>
      <address>
        <city>Wuppertal</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tolna Megyei Balassa Janos Korhaz</name>
      <address>
        <city>Borgyogyaszati Osztaly</city>
        <state>Szekszard</state>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergo-Derm Bakos Kft.</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LTD &quot;M &amp; M centrs&quot;</name>
      <address>
        <city>Adazi</city>
        <zip>2164</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arija's Ancane's Family Doctor Private Practice</name>
      <address>
        <city>Baldone</city>
        <zip>2125</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adoria Ltd</name>
      <address>
        <city>Riga</city>
        <zip>1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga 1st Hospital &quot;Skin and Sexually Transmitted Diseases Clinical Centre&quot;</name>
      <address>
        <city>Riga</city>
        <zip>1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Doctor's Indra's Kenina's Practice</name>
      <address>
        <city>Riga</city>
        <zip>1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Center of Talsi Ltd</name>
      <address>
        <city>Talsi</city>
        <zip>3201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre (Dermatology)</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross University Hospital</name>
      <address>
        <city>London</city>
        <state>LDN</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff University, Dermatology</name>
      <address>
        <city>Cardiff</city>
        <state>SGM</state>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Eliot Hospital</name>
      <address>
        <city>Nuneaton</city>
        <state>WAR</state>
        <zip>CV10 7DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust (Dermatology)</name>
      <address>
        <city>Leeds</city>
        <state>YKS</state>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Helier Hospital</name>
      <address>
        <city>London</city>
        <zip>SM5 1AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>arthritis</keyword>
  <keyword>psoriatic</keyword>
  <keyword>psoriasis</keyword>
  <keyword>palmoplantar</keyword>
  <keyword>scalp</keyword>
  <keyword>psoriasis pill</keyword>
  <keyword>psoriasis tablet</keyword>
  <keyword>plaque psoriasis</keyword>
  <keyword>plaque type psoriasis</keyword>
  <keyword>moderate to severe plaque type psoriasis</keyword>
  <keyword>psoriatic arthritis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
